Sugi Predict

Sugi Predict / Compounds / SCHEMBL1770528

SCHEMBL1770528

SCHEMBL1770528

CCOC(=O)N1CCN(Cc2ccn(Cc3ccccc3Cl)c(=O)c2O)CC1

nearest known ligand 0.73

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 9/20 0.73
▸ VEGFA P15692 4/20 0.58
▸ EGLN1 Q9GZT9 4/20 0.58
▸ KDM4E B2RXH2 6/20 0.55
▸ POLB P06746 1/20 0.55
▸ KMT2A Q03164 5/20 0.51
▸ MAPT P10636 4/20 0.51
▸ MEN1 O00255 2/20 0.51
▸ RAB9A P51151 2/20 0.51
▸ NPSR1 Q6W5P4 2/20 0.51
▸ TDP1 Q9NUW8 2/20 0.51
▸ MPI P34949 2/20 0.51
▸ ALOX15 P16050 1/20 0.51
▸ NPC1 O15118 1/20 0.51
▸ HTT P42858 1/20 0.51
▸ GAA P10253 3/20 0.49
▸ LMNA P02545 1/20 0.49
▸ TSHR P16473 2/20 0.48
▸ HSD17B10 Q99714 1/20 0.46
▸ FAAH O00519 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17005953 0.92 ALDH1A1 (0.61) ALDH1A1VEGFAEGLN1KDM4EPOLB
SCHEMBL1770342 0.91 VEGFA (0.59) ALDH1A1VEGFAEGLN1KMT2AMAPT
SCHEMBL17005843 0.90 ALDH1A1 (0.60) ALDH1A1VEGFAEGLN1KDM4EPOLB
SCHEMBL17005891 0.90 ALDH1A1 (0.57) ALDH1A1VEGFAEGLN1KDM4EPOLB
SCHEMBL20995044 0.89 VEGFA (0.72) ALDH1A1VEGFAEGLN1KDM4EPOLB
SCHEMBL17005888 0.88 VEGFA (0.61) ALDH1A1VEGFAEGLN1KDM4EPOLB
SCHEMBL17005858 0.88 VEGFA (0.61) ALDH1A1VEGFAEGLN1KDM4EPOLB
SCHEMBL1770463 0.88 VEGFA (0.75) ALDH1A1VEGFAEGLN1KDM4EPOLB
SCHEMBL17005876 0.88 KDM4E (0.55) ALDH1A1VEGFAEGLN1KDM4EPOLB
SCHEMBL17005936 0.88 KDM4E (0.55) ALDH1A1VEGFAEGLN1KDM4EPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 108 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2853265-B1 Methods for increasing the stabilization of hypoxia inducible factor-1 alpha AERPIO THERAPEUTICS INC (US) 2017-07-26 — — EP claimed
EP-2496084-B1 COMPOSITIONS AND METHODS FOR TREATING COLITIS AERPIO THERAPEUTICS INC (US) 2015-06-10 — — EP claimed
US-9045495-B2 Prolyl hydroxylase inhibitors AERPIO THERAPEUTICS INC. (US) 2015-06-02 — — US claimed
EP-2649998-B1 Prolyl hydroxylase inhibitors AERPIO THERAPEUTICS INC (US) 2015-03-04 — — EP claimed
US-8883774-B2 Methods for increasing the stabilization of hypoxia inducible factor-1 alpha AERPIO THERAPEUTICS INC. (US) 2014-11-11 — — US claimed
US-8778412-B2 Methods for increasing the stabilization of hypoxia inducible factor-1 alpha AERPIO THERAPEUTICS INC. (US) 2014-07-15 — — US claimed
EP-2649998-A1 Prolyl hydroxylase inhibitors Aerpio Therapeutics Inc. (US) 2013-10-16 — — EP claimed
US-8536181-B2 Prolyl hydroxylase inhibitors AERPIO THERAPEUTICS INC. (US) 2013-09-17 — — US claimed
US-20130158010-A1 METHODS FOR INCREASING THE STABILIZATION OF HYPOXIA INDUCIBLE FACTOR-1 ALPHA AERPIO THERAPEUTICS INC. (US) 2013-06-20 — — US claimed
US-20130158045-A1 PROLYL HYDROXYLASE INHIBITORS AERPIO THERAPEUTICS INC. (US) 2013-06-20 — — US claimed
EP-2496236-B1 PROLYL HYDROXYLASE INHIBITORS AERPIO THERAPEUTICS INC (US) 2013-05-01 — — EP claimed
US-8309537-B2 Compositions and methods for treating colitis AERPIO THERAPEUTICS INC. (US) 2012-11-13 — — US claimed
EP-2496236-A1 PROLYL HYDROXYLASE INHIBITORS Aerpio Therapeutics Inc. (US) 2012-09-12 — — EP claimed
EP-2496084-A1 COMPOSITIONS AND METHODS FOR TREATING COLITIS Aerpio Therapeutics Inc. (US) 2012-09-12 — — EP claimed
WO-2011057121-A1 COMPOSITIONS AND METHODS FOR TREATING COLITIS AKEBIA THERAPEUTICS INC. (US) 2011-05-12 — — WO claimed
US-20110112055-A1 COMPOSITIONS AND METHODS FOR TREATING COLITIS AERPIO THERAPEUTICS LLC 2011-05-12 — — US claimed
US-20110110961-A1 PROLYL HYDROXYLASE INHIBITORS AERPIO THERAPEUTICS LLC 2011-05-12 — — US claimed
WO-2011057115-A1 PROLYL HYDROXYLASE INHIBITORS AKEBIA THERAPEUTICS INC. (US) 2011-05-12 — — WO claimed
US-20220185778-A1 PROLYL HYDROXYLASE INHIBITORS AERPIO THERAPEUTICS INC (US) 2022-06-16 — — US disclosed
WO-2011057121-A1 COMPOSITIONS AND METHODS FOR TREATING COLITIS AKEBIA THERAPEUTICS INC. (US) 2011-05-12 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110112055-A1 COMPOSITIONS AND METHODS FOR TREATING COLITIS ALPI, SI, SLC10A2 ALDH1A1 780/4885VEGFA 4546/4885EGLN1 2861/4885
US-20130158045-A1 PROLYL HYDROXYLASE INHIBITORS HIF1AN, HIF1A, EGLN2 ALDH1A1 652/4885VEGFA 551/4885EGLN1 5/4885
US-20220185778-A1 PROLYL HYDROXYLASE INHIBITORS HIF1AN, HIF1A, EGLN2 ALDH1A1 652/4885VEGFA 551/4885EGLN1 5/4885
US-20130158010-A1 METHODS FOR INCREASING THE STABILIZATION OF HYPOXIA INDUCIBLE FACTOR-1 ALPHA HIF1A, HIF1AN, EGLN3 ALDH1A1 505/4885VEGFA 20/4885EGLN1 8/4885
US-20110110961-A1 PROLYL HYDROXYLASE INHIBITORS HIF1AN, HIF1A, EGLN2 ALDH1A1 652/4885VEGFA 551/4885EGLN1 5/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.